The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

Share Price Information for Beximco Pharma (BXP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 37.50
Bid: 36.00
Ask: 39.00
Change: 0.00 (0.00%)
Spread: 3.00 (8.333%)
Open: 37.50
High: 37.50
Low: 37.50
Prev. Close: 37.50
BXP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Beximco Pharma wins at Scrip Awards 2017

30 Nov 2017 10:30

RNS Number : 9866X
Beximco Pharmaceuticals Ltd
30 November 2017
 

30 November 2017

 

BEXIMCO PHARMACEUTICALS LTD.

 

Beximco Pharma wins Best Company in an Emerging Market at the 2017 Scrip Awards

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the Company has won the award for the 'Best Company in an Emerging Market' at the Scrip Awards, presented in London, England, on 29 November 2017. Rabbur Reza, Chief Operating Officer of Beximco Pharma, accepted the award on behalf of the Company.

 

In its 13th year, the Scrip Awards programme recognises the key roles that pharmaceutical, biotech and other related industries play in improving healthcare around the world. The awards provide the industry with an opportunity to acknowledge its highest achievers across all parts of the value chain and to recognise both corporate and individual achievement. A panel of 16 highly respected and independent judges from across diverse sectors evaluated the award entries to select the finalists.

 

Beximco Pharma Managing Director, Mr Nazmul Hassan MP, commented:

"I am honoured and excited that Beximco Pharma has been selected as the 'Best Company in an Emerging Market' at the prestigious Scrip Awards. As a Company that is currently exporting products to over 50 countries and producing more than 500 products encompassing broad therapeutic categories, Beximco Pharma is continuing to expand its reach and impact around the world. As the only Company in Bangladesh to export pharmaceutical products to the US, we are setting a high standard for the pharmaceutical industry in Bangladesh. I look forward to our continued advancement as we strengthen our research and development capabilities, create new partnerships and build our presence in both domestic and international markets."

 

For further information please visit www.beximco-pharma.com or enquire to:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 58611001, ext.20080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 58611891, +880 2 58612040, Ext 10140

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0)20 3368 3551 / 3555

 

Northland Capital Partners Limited (Broker)

Gerry Beaney / Tom Price

Tel: +44 (0)20 3861 6625

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0)20 3727 1000

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. Ensuring access to quality medicines is the powerful aspiration that motivates 3,500 employees of the Company.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in South East Asia, including Singapore, Thailand, Taiwan, Malaysia, Indonesia, Philippines and Hong Kong; Africa, including South Africa, Mauritius, Kenya, Ghana, Ethiopia, Uganda and Nigeria; Central Asia, including Azerbaijan; Middle East, including Kuwait and Jordan; Pacific Island countries; Latin and Central American countries; Europe, including Austria, Germany and Romania; Australia and North America, including the USA and Canada.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAWGGQPGUPMGUU
Date   Source Headline
24th Jun 20157:00 amRNSBeximco Pharma receives US FDA approval
15th Jun 20157:00 amRNSAGM Statement
14th May 20157:00 amRNSFirst Quarter Results
12th May 20157:01 amRNSAGM Notification
11th May 20157:00 amRNSAnnual Financial Report
28th Apr 20157:00 amRNSNotification of Preliminary Results and AGM
2nd Feb 20157:00 amRNSBeximco Pharma completes US FDA Audit
28th Jan 20157:00 amRNSEnters into new Loan Agreement to fund expansion
19th Jan 201512:42 pmRNSBeximco Pharma commences export to Australia
12th Dec 20147:00 amRNSAppointment of Nominated Adviser
24th Nov 20147:00 amRNSReceives GMP Approval from Health Canada
3rd Nov 20147:00 amRNSBoard Appointment
30th Oct 20147:00 amRNSFinancial Results for the Third Quarter of 2014
24th Jul 20147:00 amRNSHalf Yearly Report
14th Jul 20143:44 pmRNSPayment of Cash Dividend
4th Jul 20147:00 amRNSReceives GMP Approval from Taiwan FDA
1st Jul 201411:28 amRNSStock Dividend Issued and Total Voting Rights
23rd Jun 20147:00 amRNSAGM Statement
9th Jun 20147:30 amRNSMr. Mahbubul Alam
14th May 20147:00 amRNSFinancial Results for the First Quarter of 2014
12th May 20147:00 amRNSFinal Results
9th May 20147:00 amRNSAGM Notification
30th Apr 20147:01 amRNSNotification of Preliminary Results and AGM
22nd Apr 20147:01 amRNSMr Mohammad Abul Qasem
13th Mar 201410:13 amRNSBoard Changes
16th Jan 20142:15 pmRNSAppointment of Nominated Adviser
31st Oct 20137:00 amRNS3rd Quarter Results
1st Oct 201310:35 amRNSDr. Abdul Alim Khan
31st Jul 20137:00 amRNSHalf Year Results - 2013
17th Jul 20134:34 pmRNSShare Dividend and TVR
1st Jul 20134:30 pmRNSAGM Statement
16th May 20137:00 amRNSAGM Notification
15th May 20137:00 amRNS1st Quarter Results
14th May 20137:00 amRNSFinal Results
1st May 20137:00 amRNSNotification of Preliminary Results and AGM
4th Apr 20137:00 amRNSDirectorate Change
28th Feb 20137:00 amRNSAppointment of Corporate Broker
18th Feb 20135:13 pmRNSIssue of Equity: Share dividend admitted
11th Feb 20137:00 amRNSBeximco Pharma Enters EU Market
31st Oct 20127:00 amRNS3rd Quarter Results
31st Jul 20127:00 amRNSHalf Yearly Report
2nd Jul 20127:00 amRNSAGM Statement
18th May 20127:00 amRNSAGM Notification
16th May 20127:00 amRNS1st Quarter Results
14th May 20127:00 amRNSFinal Results
30th Apr 201212:17 pmRNSReplacement notice of AGM
30th Apr 20127:00 amRNSNotification of preliminary results and AGM
28th Oct 20117:00 amRNS3rd Quarter Results
29th Jul 20117:00 amRNSHalf Yearly Report
21st Jul 20117:00 amRNSEU GMP Certificate Received

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.